European Occupational Health Series : World Health Organization : Report on a European Syposium Convened by the Regional Office for Europe; Icp, Infection Prevention and Control Mnh 028 I-In French: La Psychiatrie Medico-Legale

By World Health Organization

Book Id: WPLBN0000156643
Format Type: PDF eBook
File Size: 1.6 MB
Reproduction Date: 2005

Title:	European Occupational Health Series : World Health Organization : Report on a European Syposium Convened by the Regional Office for Europe; Icp, Infection Prevention and Control Mnh 028 I-In French: La Psychiatrie Medico-Legale
Author:	World Health Organization
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Organization, W. H. (n.d.). European Occupational Health Series : World Health Organization : Report on a European Syposium Convened by the Regional Office for Europe; Icp, Infection Prevention and Control Mnh 028 I-In French. Retrieved from http://gutenberg.us/

Description
Medical Reference Publication

Excerpt
Introduction The Sixteenth European Symposium on Clinical Pharmacological Evaluation in Drug Control was held in Schlangenbad from 13 to 16 October 1987. The topic for the Symposium was the constraints on treatment and trials. It was attended by 40 participants from 21 countries. Dr M.N.G. Dukes welcomed the participants to the Symposium on behalf of Dr J.E. Asvall, Regional Director for Europe of the World Health Organization. He expressed the gratitude of all participants to the Ministry for Youth, Family Affairs, Women and Health of the Federal Republic of Germany for their continued generous support of the Symposium. Dr Dukes expressed the view that the continued success of these meetings must indicate that they fulfilled a widespread need in the subject. The initial symposia were held against a background of expansion in health care budgets. However, since the early 1980s the world economy has been in recession and this behoves us to cut our cloth differently. There clearly are financial constraints on drug therapy and this Symposium should help to find ways of delivering drug therapy more economically and without a reduction in standards. On behalf of the Ministry for Youth, Family Affairs, Women and Health, Dr Schorn welcomed participants to the Symposium. He expressed the view that communication and the ability to exchange information was particularly important in the modern era. He felt that international exchange of information about such things as side effects of drugs could best be achieved on a basis of sound education in pharmacology and clinical pharmacology. The meeting then elected Professor W. Dolle as its Chairperson with Dr V.K. Lepakhin and Ms N. Inan as the two Vice-Chairpeople. Professor Dolle introduced the first session of the Symposium. The effects of restrictions on prescribing The first theme concerned the impact on the health services taking as the theme less money - does it mean less care?. It was pointed out that it now costs some US $250 million to develop a new marketable medicine and it is debatable whether all this expenditure is really necessary. It was suggested that less money did not necessarily mean less care and a number of questions needed to be asked. Physicians should think whether the medicine they use is really necessary, and if it was necessary, was it the most effective one available, and perhaps the most important question was would the patient comply with the therapy? It was felt that a lot of prescribing was unnecessary and that the physician could be helped in this self-audit process by being given a list of his or her prescriptions in the previous month or so. Other questions were aimed at the pharmaceutical industry. Do they really need to spend so much money promoting a drug and Is this drug really needed?. The regulatory agency should also ask if the requirements for licensing could be eased. In discussion a number of points were raised although no concrete answers emerged. How do we judge whether a new drug really is needed? Should a licence authority consider financial aspects in the licensing of a new drug? On the economic front it was generally agreed that scientific aspects should take prime place in the assessment of a new drug. Only when these were satisfied should a comparison of costs be considered, preferably by a different group.

Table of Contents
CONTENTS Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 The effects of restrictions on prescribing . . . . . . . . . . . . . 1 Restraints on clinical trials . . . . . . . . . . . . . . . . . 2 What kind of clinical trials should be carried out in general practice? . . . . . . . . . . . . . . . . . . . . . . . . . 4 Training in clinical pharmacology in medical schools in Europe . . . . . 8 Clinical pharmacology in primary health care . . . . . . . . . . . . . . 9 Adverse drug reactions in general practice . . . . . . . . . . . . . . . 9 Patient package inserts (PPI's) . . . . . . . . . . . . . . . . . . 10 Restrictions on prescribing Conclusions . . . . . . . . . . . . . . . . . . . . . . . 11 Recommendations . . . . . . . . . . . . . . . . . . . . . . 11 Restraints on clinical trials Conclusions . . . . . . . . . . . . . . . . . . . . . . . 11 Clinical trials in general practice Recommendations . . . . . . . . . . . . . . . . . . . . . . 13 Training in clinical pharmacology in medical schools in Europe Conclusions . . . . . . . . . . . . . . . . . . . . . . . 14 Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Clinical pharmacology in primary health care Conclusions . Recommendatio. ns. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..i . . . . . . . . 14 . . . . . . . 14 Adverse drug reactions in general practice Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Annex 1 . List of participants . . . . . . . . . . . . . . . . . . . . . . 17